1. AB039. Pragmatic trial stepping down Flutiform® in patients maintained on high dose ICS
- Author
-
Elizabeth Gardener, Anu Kemppinen, Vicky Thomas, Christina Callan, Vanessa Woodhead, Elizabeth F. Juniper, David Price, Omar S. Usmani, Andrew McLoughlin, Peter J. Barnes, Priyanka Raju, and Adam Brady
- Subjects
Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,Asthma therapy ,business.industry ,Inhaled corticosteroids ,medicine.disease ,Poster Session ,Pragmatic trial ,respiratory tract diseases ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Anesthesia ,medicine ,High doses ,In patient ,030212 general & internal medicine ,Formoterol ,business ,030217 neurology & neurosurgery ,medicine.drug ,Fluticasone ,Asthma - Abstract
Background Global Initiative for Asthma (GINA) guidelines recommend a gradual step-down of asthma therapy if asthma has been well-controlled for at least 3 months. In real life, however, many well-controlled patients are prescribed high doses of inhaled corticosteroids (ICS), and are therefore unnecessarily at risk of systemic side effects associated with long-term ICS use. To encourage and facilitate step-down in a clinical setting, further pragmatic studies are required to demonstrate that good control of asthma can be maintained with a lower dose of ICS in stable and controlled patients, and to explore potential predictors for response to step-down.To test if good control of asthma can be maintained in adult patients previously stable on Flutiform® 250 (250 mcg fluticasone/10 mcg formoterol) for 12 weeks, after step-down to Flutiform® 125 (250 mcg fluticasone/5 mcg formoterol).
- Published
- 2016